SG11201509764RA - Pharmaceutical formulations of a hif hydroxylase inhibitor - Google Patents

Pharmaceutical formulations of a hif hydroxylase inhibitor

Info

Publication number: SG11201509764RA
Authority: SG; Singapore
Prior art keywords: pharmaceutical formulations; hydroxylase inhibitor; hif hydroxylase; hif; inhibitor
Prior art date: 2013-06-06

Application number

SG11201509764RA

Other languages

English (en)

Inventor

David Conca

Lee Allen Flippin

Scott David Leigh

Claudia Witschi

Lee Robert Wright

Original Assignee

Fibrogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-06

Filing date

2014-06-05

Publication date

2015-12-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201509764R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-05 Application filed by Fibrogen Inc filed Critical Fibrogen Inc

2015-12-30 Publication of SG11201509764RA publication Critical patent/SG11201509764RA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG11201509764RA 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor SG11201509764RA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361831909P	2013-06-06	2013-06-06
PCT/US2014/041021 WO2014197660A1 (en)	2013-06-06	2014-06-05	Pharmaceutical formulations of a hif hydroxylase inhibitor

Publications (1)

Publication Number	Publication Date
SG11201509764RA true SG11201509764RA (en)	2015-12-30

Family

ID=51063834

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201509764RA SG11201509764RA (en)	2013-06-06	2014-06-05	Pharmaceutical formulations of a hif hydroxylase inhibitor

Country Status (24)

Country	Link
US (3)	US20160120859A1 (el)
EP (2)	EP3708154A1 (el)
JP (4)	JP6604941B2 (el)
KR (3)	KR102291860B1 (el)
CN (5)	CN111728951A (el)
AU (1)	AU2014274890B2 (el)
CA (1)	CA2914049C (el)
CY (1)	CY1122951T1 (el)
DK (1)	DK3003284T3 (el)
ES (1)	ES2786924T3 (el)
HR (1)	HRP20200615T1 (el)
HU (1)	HUE049623T2 (el)
IL (3)	IL298998B2 (el)
LT (1)	LT3003284T (el)
ME (1)	ME03777B (el)
MX (3)	MX2015016536A (el)
PL (1)	PL3003284T3 (el)
PT (1)	PT3003284T (el)
RS (1)	RS60464B1 (el)
SG (1)	SG11201509764RA (el)
SI (1)	SI3003284T1 (el)
SM (1)	SMT202000190T1 (el)
WO (1)	WO2014197660A1 (el)
ZA (1)	ZA201508712B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2362032T3 (es)	2003-06-06	2011-06-27	Fibrogen, Inc.	Compuestos de heteroarilo que contienen nitrógeno y su uso en el aumento de eritropoyetina endógena.
CN105037323A (zh)	2008-11-14	2015-11-11	菲布罗根有限公司	作为hif羟化酶抑制剂的苯并噻喃衍生物
US8883823B2 (en)	2012-07-16	2014-11-11	Fibrogen, Inc.	Crystalline forms of a prolyl hydroxylase inhibitor
KR102149380B1 (ko)	2012-07-16	2020-08-28	피브로겐, 인크.	프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
CN106083719B (zh)	2012-07-16	2019-10-18	菲布罗根有限公司	制备异喹啉化合物的方法
WO2014197660A1 (en)	2013-06-06	2014-12-11	Fibrogen, Inc.	Pharmaceutical formulations of a hif hydroxylase inhibitor
LT3277270T (lt) *	2015-04-01	2022-01-10	Akebia Therapeutics, Inc.	Kompozicijos ir būdai skirti anemijos gydymui
WO2019042485A1 (en)	2017-08-30	2019-03-07	Zentiva, K.S.	FORMS IN THE STRONG STATE OF ROXADUSTAT
PL3679017T3 (pl)	2017-09-04	2022-01-17	Sandoz Ag	Kokryształ doustnie dostępnego inhibitora hydroksylazy prolilowej hif
CN110664814A (zh) *	2019-10-24	2020-01-10	上海长海医院	Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) *	2019-12-17	2022-08-19	河北长天药业有限公司	一种复方氨酚那敏颗粒
JP2023518392A (ja) *	2020-03-17	2023-05-01	ザイダスライフサイエンシズリミティド	Ｈｉｆプロリルヒドロキシラーゼ阻害剤を含む製剤組成物
WO2022192097A1 (en) *	2021-03-06	2022-09-15	Mind Medicine, Inc.	Formulations of psilocin that have enhanced stability
CN114796280B (zh) *	2022-06-15	2024-06-25	河北长天药业有限公司	一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) *	2022-08-08	2024-02-14	Sanovel Ilac Sanayi Ve Ticaret A.S.	An oral pharmaceutical composition comprising roxadustat
WO2025111214A1 (en)	2023-11-22	2025-05-30	Fibrogen, Inc.	[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds)
CN118436652A (zh) *	2024-04-18	2024-08-06	南方医科大学顺德医院(佛山市顺德区第一人民医院)	一种罗沙司他药物制剂及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE149486T1 (de)	1993-11-02	1997-03-15	Hoechst Ag	Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
DE19746287A1 (de)	1997-10-20	1999-04-22	Hoechst Marion Roussel De Gmbh	Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2467689C (en)	2001-12-06	2013-10-01	Fibrogen, Inc.	Stabilization of hypoxia inducible factor (hif) alpha using inhibitors of hif prolyl hydroxylase
US8318703B2 (en)	2001-12-06	2012-11-27	Fibrogen, Inc.	Methods for improving kidney function
DE10209692A1 (de)	2002-03-06	2003-09-18	Merck Patent Gmbh	Isochinolinderivate
US7618940B2 (en)	2002-12-06	2009-11-17	Fibrogen, Inc.	Fat regulation
US8124582B2 (en)	2002-12-06	2012-02-28	Fibrogen, Inc.	Treatment of diabetes
JP4805234B2 (ja) *	2002-12-16	2011-11-02	キッセイ薬品工業株式会社	経口固形医薬
CN101069685B (zh)	2002-12-16	2011-12-14	橘生药品工业株式会社	固体口服剂型药物
US8614204B2 (en)	2003-06-06	2013-12-24	Fibrogen, Inc.	Enhanced erythropoiesis and iron metabolism
ES2362032T3 (es)	2003-06-06	2011-06-27	Fibrogen, Inc.	Compuestos de heteroarilo que contienen nitrógeno y su uso en el aumento de eritropoyetina endógena.
EP1658074B1 (en)	2003-08-01	2012-11-07	Fibrogen, Inc.	Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
JP4789264B2 (ja)	2004-03-16	2011-10-12	旭化成ファーマ株式会社	ファスジル含有製剤及びその安定性を改善する方法
EP1866318B1 (en)	2005-03-02	2011-06-22	Fibrogen, Inc.	Thienopyridine compounds, and methods of use thereof
US20060276477A1 (en)	2005-06-06	2006-12-07	Fibrogen, Inc.	Treatment method for anemia
AU2006259352A1 (en)	2005-06-15	2006-12-28	Fibrogen, Inc.	Use of HIF 1alfa modulators for treatment of cancer
UA97349C2 (uk)	2005-09-08	2012-02-10	Х. Луннбэк А/С	Стійкі тверді склади сертиндолу
PT1944029E (pt)	2005-10-31	2012-02-09	Nissan Chemical Ind Ltd	Preparação farmacêutica com excelente fotoestabilidade
GB0523810D0 (en)	2005-11-23	2006-01-04	Astrazeneca Ab	Pharmaceutical compositions
MX2008009581A (es)	2006-01-27	2009-01-07	Fibrogen Inc	Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih).
ATE464902T1 (de) *	2006-02-09	2010-05-15	Teva Pharma	Stabile pharmazeutische zubereitungen von montelukast-natrium
US20070259960A1 (en)	2006-02-16	2007-11-08	Fibrogen, Inc.	Compounds and methods for treatment of stroke
BRPI0710527B8 (pt)	2006-04-04	2021-05-25	Fibrogen Inc	compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20100172984A1 (en) *	2006-06-06	2010-07-08	Bijay Kumar Padhi	tablet dosage form comprising cetirizine and pseudoephedrine
US20070293575A1 (en)	2006-06-15	2007-12-20	Fibrogen, Inc.	Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en)	2006-06-15	2010-05-11	Fibrogen, Inc.	Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja)	2007-04-27	2015-03-11	ニプロ株式会社	経口固形製剤及びその製造方法
EP2209501B1 (en) *	2007-10-12	2011-12-14	AstraZeneca AB	Zibotentan composition containing mannitol and microcrystalline cellulose
WO2009058403A1 (en)	2007-11-02	2009-05-07	Fibrogen, Inc.	Methods for reducing blood pressure
US8269008B2 (en)	2007-12-03	2012-09-18	Fibrogen, Inc.	Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009075824A1 (en)	2007-12-06	2009-06-18	Fibrogen, Inc.	Methods for increasing endothelial progentior cells
EP2231156A1 (en)	2007-12-07	2010-09-29	Fibrogen, Inc.	Methods for increasing white blood cells
WO2009089547A1 (en)	2008-01-11	2009-07-16	Fibrogen, Inc.	Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en)	2008-02-05	2009-08-13	Fibrogen, Inc.	Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
CN102264740B (zh)	2008-08-20	2014-10-15	菲布罗根有限公司	一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
US20110263642A1 (en)	2008-08-26	2011-10-27	Fibrogen, Inc.	Methods for treatment of multiple sclerosis
CN105037323A (zh)	2008-11-14	2015-11-11	菲布罗根有限公司	作为hif羟化酶抑制剂的苯并噻喃衍生物
US20100144737A1 (en)	2008-12-08	2010-06-10	Fibrogen, Inc.	Methods for inhibiting t helper cell differentiation
EP2382971A4 (en)	2009-01-29	2014-01-08	Dainippon Sumitomo Pharma Co	ORAL DISINTEGRATING TABLE COMPRISING AN INDOOR CORE
JP2010248106A (ja) *	2009-04-14	2010-11-04	Dainippon Sumitomo Pharma Co Ltd	フィルムコーティング錠
JP2012176899A (ja)	2009-05-19	2012-09-13	Mitsubishi Tanabe Pharma Corp	２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
US20140057941A1 (en)	2011-01-13	2014-02-27	Kin-Hung (Peony) Yu	Methods For Increasing Mean Corpuscular Volume
WO2012097331A1 (en) *	2011-01-13	2012-07-19	Fibrogen, Inc.	Methods for increasing reticulocyte hemoglobin content
EP2670750B1 (en)	2011-02-02	2016-09-14	Fibrogen, Inc.	Naphthyridine derivatives as inhibitors of hypoxia inducible factor
KR102029951B1 (ko)	2011-07-22	2019-11-08	베이징 베타 파머수티컬 컴퍼니 리미티드	프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
US20140309256A1 (en)	2011-11-09	2014-10-16	Fibrogen, Inc.	Therapeutic Method
CA2866556C (en)	2012-03-09	2020-01-07	Fibrogen, Inc.	4 -hydroxy-isoquinoline compounds as hif hydroxylase inhibitors
CN106083719B (zh)	2012-07-16	2019-10-18	菲布罗根有限公司	制备异喹啉化合物的方法
KR102149380B1 (ko)	2012-07-16	2020-08-28	피브로겐, 인크.	프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
US8883823B2 (en)	2012-07-16	2014-11-11	Fibrogen, Inc.	Crystalline forms of a prolyl hydroxylase inhibitor
TWI685487B (zh)	2013-01-24	2020-02-21	美商費比羅根公司	｛［１-氰基-５-（４-氯苯氧基）-４-羥基-異喹啉-３-羰基］-胺基｝-乙酸之晶形
WO2014197660A1 (en)	2013-06-06	2014-12-11	Fibrogen, Inc.	Pharmaceutical formulations of a hif hydroxylase inhibitor

2014
- 2014-06-05 WO PCT/US2014/041021 patent/WO2014197660A1/en not_active Application Discontinuation
- 2014-06-05 JP JP2016517984A patent/JP6604941B2/ja active Active
- 2014-06-05 CN CN202010591483.2A patent/CN111728951A/zh active Pending
- 2014-06-05 MX MX2015016536A patent/MX2015016536A/es active IP Right Grant
- 2014-06-05 DK DK14735770.1T patent/DK3003284T3/da active
- 2014-06-05 HU HUE14735770A patent/HUE049623T2/hu unknown
- 2014-06-05 EP EP20156653.6A patent/EP3708154A1/en active Pending
- 2014-06-05 ES ES14735770T patent/ES2786924T3/es active Active
- 2014-06-05 CN CN202010591484.7A patent/CN111728952A/zh active Pending
- 2014-06-05 CN CN201910744577.6A patent/CN110448537A/zh active Pending
- 2014-06-05 KR KR1020157034392A patent/KR102291860B1/ko active Active
- 2014-06-05 SI SI201431529T patent/SI3003284T1/sl unknown
- 2014-06-05 CN CN202010591474.3A patent/CN111728950A/zh active Pending
- 2014-06-05 PL PL14735770T patent/PL3003284T3/pl unknown
- 2014-06-05 CA CA2914049A patent/CA2914049C/en active Active
- 2014-06-05 CN CN201480031209.2A patent/CN105377242A/zh active Pending
- 2014-06-05 KR KR1020227041268A patent/KR20220164069A/ko not_active Ceased
- 2014-06-05 SM SM20200190T patent/SMT202000190T1/it unknown
- 2014-06-05 HR HRP20200615TT patent/HRP20200615T1/hr unknown
- 2014-06-05 PT PT147357701T patent/PT3003284T/pt unknown
- 2014-06-05 SG SG11201509764RA patent/SG11201509764RA/en unknown
- 2014-06-05 EP EP14735770.1A patent/EP3003284B1/en not_active Revoked
- 2014-06-05 IL IL298998A patent/IL298998B2/en unknown
- 2014-06-05 ME MEP-2020-79A patent/ME03777B/me unknown
- 2014-06-05 AU AU2014274890A patent/AU2014274890B2/en active Active
- 2014-06-05 KR KR1020217025795A patent/KR20210104173A/ko not_active Ceased
- 2014-06-05 RS RS20200417A patent/RS60464B1/sr unknown
- 2014-06-05 US US14/896,353 patent/US20160120859A1/en not_active Abandoned
- 2014-06-05 IL IL296484A patent/IL296484B2/en unknown
- 2014-06-05 LT LTEP14735770.1T patent/LT3003284T/lt unknown
2015
- 2015-11-24 IL IL242759A patent/IL242759B2/en unknown
- 2015-11-26 ZA ZA2015/08712A patent/ZA201508712B/en unknown
- 2015-12-01 MX MX2020003096A patent/MX2020003096A/es unknown
- 2015-12-01 MX MX2022011225A patent/MX2022011225A/es unknown
2018
- 2018-07-13 US US16/035,503 patent/US10765672B2/en active Active
2019
- 2019-06-04 JP JP2019104562A patent/JP6861758B2/ja active Active
2020
- 2020-04-27 CY CY20201100383T patent/CY1122951T1/el unknown
2021
- 2021-03-10 US US17/198,013 patent/US20220054474A1/en not_active Abandoned
- 2021-03-30 JP JP2021057424A patent/JP2021100971A/ja not_active Withdrawn
2023
- 2023-03-27 JP JP2023049709A patent/JP2023068197A/ja active Pending

Also Published As

Publication number	Publication date
IL296484B1 (en)	2024-11-01
ES2786924T3 (es)	2020-10-14
MX2020003096A (es)	2020-08-17
ME03777B (me)	2021-04-20
LT3003284T (lt)	2020-04-27
EP3708154A1 (en)	2020-09-16
KR102291860B1 (ko)	2021-08-20
EP3003284B1 (en)	2020-02-12
KR20210104173A (ko)	2021-08-24
JP2021100971A (ja)	2021-07-08
CN111728952A (zh)	2020-10-02
IL296484B2 (en)	2025-03-01
JP2023068197A (ja)	2023-05-16
EP3003284A1 (en)	2016-04-13
CA2914049A1 (en)	2014-12-11
IL298998B2 (en)	2024-07-01
RS60464B1 (sr)	2020-07-31
US20160120859A1 (en)	2016-05-05
PT3003284T (pt)	2020-08-10
HUE049623T2 (hu)	2020-09-28
RU2015151056A (ru)	2017-07-14
MX2022011225A (es)	2022-10-07
IL298998A (en)	2023-02-01
IL296484A (en)	2022-11-01
US20220054474A1 (en)	2022-02-24
BR112015029693A2 (pt)	2017-07-25
HK1222550A1 (en)	2017-07-07
IL298998B1 (en)	2024-03-01
US10765672B2 (en)	2020-09-08
KR20220164069A (ko)	2022-12-12
CN111728951A (zh)	2020-10-02
WO2014197660A1 (en)	2014-12-11
NZ714554A (en)	2021-06-25
BR112015029693A8 (pt)	2019-12-24
RU2681304C2 (ru)	2019-03-06
SMT202000190T1 (it)	2020-05-08
CN110448537A (zh)	2019-11-15
CA2914049C (en)	2021-10-12
MX2015016536A (es)	2016-08-11
RU2015151056A3 (el)	2018-05-03
AU2014274890B2 (en)	2019-10-03
AU2014274890A1 (en)	2015-12-17
JP6861758B2 (ja)	2021-04-21
CY1122951T1 (el)	2021-10-29
KR20160018514A (ko)	2016-02-17
JP2019137703A (ja)	2019-08-22
JP6604941B2 (ja)	2019-11-13
NZ754196A (en)	2021-06-25
IL242759A (el)	2015-12-31
IL242759B2 (en)	2023-05-01
CN111728950A (zh)	2020-10-02
ZA201508712B (en)	2020-07-29
PL3003284T3 (pl)	2020-08-10
JP2016523846A (ja)	2016-08-12
CN105377242A (zh)	2016-03-02
SI3003284T1 (sl)	2020-08-31
DK3003284T3 (da)	2020-03-30
HRP20200615T1 (hr)	2020-07-10
US20190008846A1 (en)	2019-01-10
IL242759B1 (en)	2023-01-01

Publication	Publication Date	Title
ZA201508712B (en)	2020-07-29	Pharmaceutical formulations of a hif hydroxylase inhibitor
PT3080100T (pt)	2023-01-19	Inibidores de desmetilase-1 específica de lisina
IL264259A (en)	2019-02-28	Oral formulations of pyrrolidine derivatives
IL240277A0 (en)	2015-09-24	Solid forms of a selective inhibitor of cdk4/6
SG11201405574UA (en)	2014-10-30	4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
IL252834A0 (en)	2017-08-31	A process for making a pde4 inhibitor
IL240557A0 (en)	2015-10-29	Formulations of laquinimod for transdermal administration
AP2014007760A0 (en)	2014-07-31	Stabilized pharmaceutical formulations of a potentHCV inhibitor
PL2801352T3 (pl)	2017-12-29	Ulegające rozpadowi w jamie ustnej formulacje lakozamidu
GB201320835D0 (en)	2014-01-08	HIF inhibitors
EP3052475A4 (en)	2017-05-03	Pharmaceutical use of 3-benzylsulfonylpropionitrile